Some Antineoplastic Antibiotics

Cheng, C. C.; Zee-Cheng, Kwang-Yuen

doi:10.1002/jps.2600610402

Cited by 10 publications

(2 citation statements)

References 235 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is partially supported by demonstration of cross-resistance between mitomycinresistant tumors and the use of other alkylating agents (3). However, this observation is not borne out in our study since 13 of 14 objective responders had already proven resistant to prior alkylator therapy.…”

Section: Discussionmentioning

confidence: 69%

See 1 more Smart Citation

Mitomycin C in large infrequent doses in breast cancer

Wise

Kuhn

Godfrey

1976

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Seventy-one women with far-advanced breast cancer resistant to standard chemotherapeutic agents were administered mitomycin C using an intermittent high dose schedule. One group consisted of 54 patients with measurable metastatic tumor; a second group consisted of 18 patients with nonmeasurable osseous metastases. Objective response rate in group 1 was 26% for an average duration of 2 1/2 months. Subjective response rate in group 2 was 44% for an average duration of 3 months. Response and toxicity data were similar to those of studies employing the less convenient protracted low-dose schedule. Prior treatment with other alkylating agents did not adversely affect response. Further investigation into the role of mitomycin in combination chemotherapy programs is recommended.

show abstract

Section: Discussionmentioning

confidence: 69%

“…Also possessing antineoplastic activity, this deep blue-violet compound is thought to have a mechanism of action similar to that of the alkylating agents (1)(2)(3)(4). For the past 15 years extensive research has documented its effectiveness in several types of human cancer.…”

mentioning

confidence: 99%